• News
  • SAN DIEGO
  • BioTech

Celladon announces new patent

Celladon Corp., a privately held San Diego biotechnology company, announced Wednesday that the U.S. Patent and Trademark Office has issued a notice of allowance for its U.S. patent application relative to the company's small molecule program that targets SERCA enzymes.

The patent application covers methods for identifying compounds that modulate Sarco/Endoplamic Reticulum Calcium ATPase (SERCA) and methods for identifying compounds that modulate the SERCA/phospholamban complex using Celladon's proprietary fluorescence resonance energy transfer assay.

The patent, titled "Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium ATPase and phospholamban," is expected to issue later this year and is expected to provide a patent term to January 2030, the company said in a release. The company credits Dr. David D. Thomas of the University of Minnesota with inventing the patent, and it will be jointly owned by Celladon and the University of Minnesota. Celladon retains an exclusive license to use, develop and commercialize it.

"The SERCA2b/ER stress pathway provides multiple opportunities for drug discovery and development in a number of disease areas with great unmet need," said Dr. Krisztina Zsebo, president and CEO of Celladon. "This allowance further strengthens Celladon's leading position of generating active compounds in this emerging field."

Using the screening assay, Celladon reports having developed a broad platform of small molecule allosteric modulators of the SERCA2b enzyme-generating drug candidates targeting diseases such as diabetes and neurodegenerative diseases.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.